Trials / Completed
CompletedNCT00513565
A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers
A Randomised, Placebo-controlled, Double-dummy, Crossover Design Study to Investigate the Changes of fMRI BOLD Activation Induced by Emotional Activation Paradigms Following Single Doses of GSK561679 and Lorazepam (Comparator) in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This study will be conducted in healthy volunteers to investigate the effect of single dose GSK561679 on the changes of brain activation, as it compares to an active comparator, lorazepam.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | single dose | Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session. |
Timeline
- Start date
- 2007-09-13
- Primary completion
- 2009-05-14
- Completion
- 2009-05-14
- First posted
- 2007-08-08
- Last updated
- 2017-07-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00513565. Inclusion in this directory is not an endorsement.